BR0317253A - Derivados pregabalina para o tratamento da fibromialgia e outras patologias - Google Patents
Derivados pregabalina para o tratamento da fibromialgia e outras patologiasInfo
- Publication number
- BR0317253A BR0317253A BR0317253-8A BR0317253A BR0317253A BR 0317253 A BR0317253 A BR 0317253A BR 0317253 A BR0317253 A BR 0317253A BR 0317253 A BR0317253 A BR 0317253A
- Authority
- BR
- Brazil
- Prior art keywords
- carbon atoms
- fibromyalgia
- straight
- treatment
- agoraphobia
- Prior art date
Links
- 208000001640 Fibromyalgia Diseases 0.000 title abstract 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical class CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 208000008811 Agoraphobia Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 (3S, 5R) -3-aminomethyl-5-methyloctanoic acid compound Chemical class 0.000 abstract 1
- 206010034912 Phobia Diseases 0.000 abstract 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
- 208000007656 osteochondritis dissecans Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000001716 specific phobia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"DERIVADOS PREGABALINA PARA O TRATAMENTO DA FIBROMIALGIA E OUTRAS PATOLOGIAS". A presente invenção se refere a um método para o tratamento de uma patologia selecionada de OCD, agorafobia, agorafobia sem um histórico de perturbação de pânico, fobia específica, fobia social, PTSD, síndrome das pernas irrequietas, transtorno disfórico pré-menstrual, ondas de calor, e fibromialgia por administração de um composto de fórmula 1 ou um seu sal farmaceuticamente aceitável, onde: (a) R¬ 1¬ é hidrogênio, alquila linear ou ramificada de 1 a 6 átomos de carbono ou fenila; e (b) R¬ 2¬ é alquila linear ou ramificada de 4 a 8 átomos de carbono, alcenila linear ou ramificada de 2 a 8 átomos de carbono, cicloalquila de 3 a 7 átomos de carbono, alcoxila de 1 a 6 átomos de carbono, alquilcicloalquila, -alquilalcoxila, -alquila OH, - alquilfenila, -alquilfenoxila, ou -fenila substituída. A invenção também se refere a um método para o tratamento das patologias acima por administração do composto ácido (3S,5R)-3-aminometil-5-metil-octanóico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43349102P | 2002-12-13 | 2002-12-13 | |
| US48774003P | 2003-07-16 | 2003-07-16 | |
| PCT/IB2003/005712 WO2004054566A1 (en) | 2002-12-13 | 2003-12-03 | Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317253A true BR0317253A (pt) | 2005-11-01 |
Family
ID=32600153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317253-8A BR0317253A (pt) | 2002-12-13 | 2003-12-03 | Derivados pregabalina para o tratamento da fibromialgia e outras patologias |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090203782A1 (pt) |
| EP (2) | EP1572188A1 (pt) |
| JP (1) | JP2006513257A (pt) |
| KR (1) | KR20050085636A (pt) |
| CN (1) | CN101862317A (pt) |
| AU (1) | AU2003303040B2 (pt) |
| BR (1) | BR0317253A (pt) |
| CA (1) | CA2505788A1 (pt) |
| MX (1) | MXPA05006320A (pt) |
| NO (1) | NO20052264L (pt) |
| NZ (1) | NZ540591A (pt) |
| PL (1) | PL377520A1 (pt) |
| RU (2) | RU2353358C2 (pt) |
| TW (1) | TW200423925A (pt) |
| WO (1) | WO2004054566A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05010515A (es) | 2003-03-31 | 2006-03-10 | Xenoport Inc | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. |
| KR20060087560A (ko) * | 2003-09-12 | 2006-08-02 | 워너-램버트 캄파니 엘엘씨 | 알파-2-델타 리간드 및 ssri 및/또는 snri를포함하는 우울증 및 불안 장애 치료용 조합물 |
| US20070141684A1 (en) | 2005-12-21 | 2007-06-21 | Pfizer Inc | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein |
| US9394236B2 (en) | 2014-02-03 | 2016-07-19 | Quadriga Biosciences, Inc. | β-substituted γ-amino acids and analogs as chemotherapeutic agents |
| WO2015117147A1 (en) | 2014-02-03 | 2015-08-06 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| CA2994404C (en) | 2015-08-03 | 2020-12-08 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
| CN115739134B (zh) * | 2022-11-24 | 2024-08-02 | 贵州大学 | 一种利用三氯化钌废弃物制备氯乙烯合成用复合催化剂的方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| RU94046105A (ru) | 1992-05-20 | 1997-06-20 | Нортвестерн Юниверсити (Us) | АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| CA2150703C (en) | 1992-12-17 | 2002-01-08 | Pfizer Limited | Substituted pyrazoles |
| US5712303A (en) | 1992-12-17 | 1998-01-27 | Pfizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
| ES2128544T3 (es) | 1992-12-17 | 1999-05-16 | Pfizer | Pirrolopirimidinas como antagonistas del crf. |
| TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
| US5670539A (en) * | 1993-07-21 | 1997-09-23 | New York State Office Of Mental Health | Treatment of movement disorders using large neutral amino acids |
| US6372792B1 (en) * | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| US6001876A (en) * | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| NZ334898A (en) | 1996-10-23 | 2000-09-29 | Warner Lambert Co | Substituted gamma aminobutyric acids as pharamceutical agents |
| US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
| KR100589066B1 (ko) | 1997-10-27 | 2006-06-13 | 워너-램버트 캄파니 엘엘씨 | 약제로서 유용한 시클릭 아미노산 및 그의 유도체 |
| US6306910B1 (en) | 1998-07-09 | 2001-10-23 | Warner-Lambert Company | Use of Gaba-analogues for treating insomnia |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000061188A1 (en) * | 1999-04-09 | 2000-10-19 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
| US6642398B2 (en) * | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
| CA2374755C (en) * | 1999-06-10 | 2010-03-30 | Warner-Lambert Company | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| NZ517044A (en) * | 1999-07-22 | 2004-02-27 | Univ Rochester | Gamma-aminobutyric acid analogues, e.g. gabapentin and pregabalin, to treat symptoms of hormonal variation, including hot flushes, nausea, emesis and fever |
| US6281207B1 (en) * | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
| HN2000000224A (es) | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| GB2365425A (en) * | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| WO2002069974A1 (en) * | 2001-03-05 | 2002-09-12 | Andrew Holman | Administration of sleep restorative agents |
| BR0209973A (pt) * | 2001-05-25 | 2004-04-06 | Warner Lambert Co | Composição farmacêutica lìquida |
-
2003
- 2003-12-03 CN CN201010165706A patent/CN101862317A/zh active Pending
- 2003-12-03 WO PCT/IB2003/005712 patent/WO2004054566A1/en not_active Ceased
- 2003-12-03 MX MXPA05006320A patent/MXPA05006320A/es active IP Right Grant
- 2003-12-03 KR KR1020057010833A patent/KR20050085636A/ko not_active Ceased
- 2003-12-03 PL PL377520A patent/PL377520A1/pl not_active Application Discontinuation
- 2003-12-03 NZ NZ540591A patent/NZ540591A/en unknown
- 2003-12-03 EP EP03813230A patent/EP1572188A1/en not_active Withdrawn
- 2003-12-03 EP EP09175270A patent/EP2172197A1/en not_active Withdrawn
- 2003-12-03 CA CA002505788A patent/CA2505788A1/en not_active Abandoned
- 2003-12-03 AU AU2003303040A patent/AU2003303040B2/en not_active Ceased
- 2003-12-03 JP JP2005502471A patent/JP2006513257A/ja active Pending
- 2003-12-03 BR BR0317253-8A patent/BR0317253A/pt not_active IP Right Cessation
- 2003-12-03 RU RU2005118081/14A patent/RU2353358C2/ru not_active IP Right Cessation
- 2003-12-12 TW TW092135197A patent/TW200423925A/zh unknown
-
2005
- 2005-05-10 NO NO20052264A patent/NO20052264L/no not_active Application Discontinuation
-
2008
- 2008-10-13 RU RU2008140653/15A patent/RU2008140653A/ru unknown
-
2009
- 2009-04-20 US US12/426,501 patent/US20090203782A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006513257A (ja) | 2006-04-20 |
| NO20052264D0 (no) | 2005-05-10 |
| NO20052264L (no) | 2005-09-12 |
| NZ540591A (en) | 2008-03-28 |
| TW200423925A (en) | 2004-11-16 |
| CA2505788A1 (en) | 2004-07-01 |
| CN101862317A (zh) | 2010-10-20 |
| WO2004054566A1 (en) | 2004-07-01 |
| EP1572188A1 (en) | 2005-09-14 |
| US20090203782A1 (en) | 2009-08-13 |
| EP2172197A1 (en) | 2010-04-07 |
| AU2003303040A1 (en) | 2004-07-09 |
| PL377520A1 (pl) | 2006-02-06 |
| RU2005118081A (ru) | 2006-01-20 |
| KR20050085636A (ko) | 2005-08-29 |
| RU2353358C2 (ru) | 2009-04-27 |
| AU2003303040B2 (en) | 2009-04-23 |
| MXPA05006320A (es) | 2005-08-26 |
| RU2008140653A (ru) | 2010-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0610087A2 (pt) | composto para resfriamento | |
| RU2203274C2 (ru) | Спироциклические ингибиторы металлопротеаз | |
| BR0210721A (pt) | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição | |
| EA200501098A1 (ru) | Антибактериальные агенты | |
| RU2002124873A (ru) | Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных | |
| BR0315781A (pt) | Composição para tratamento de infecção causada por vìrus flaviviridae | |
| BRPI0419067A (pt) | método para aumento da cognição utilizando ziprasidona | |
| TW200509886A (en) | Therapeutic agent | |
| PT1653943E (pt) | Derivados de catecol para o tratamento do cancro | |
| EA200800303A1 (ru) | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами | |
| RU2009127750A (ru) | Препарат против helicobacter pylori, ингибирующий секрецию желудочного сока | |
| BR0007784A (pt) | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto | |
| BG101896A (en) | Pyrrolidinylhydroxamic acid compounds and method for their preparation | |
| DE69929362D1 (de) | verwendung von 1,4-benzothiazepinen zur Herstellung eines Medikaments ZUR BEHANDLUNG DER VORHOF-FIBRILLATION | |
| BR0307411A (pt) | Ligantes alfa2delta para tratar zumbidos | |
| BRPI0409151A (pt) | uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos | |
| BR0312385A (pt) | Preparação, processos para produzir a mesma e uma ração contendo diformiato e/ou aditivo de ração, uso de uma preparação, e, ração animal | |
| EP1627635A3 (en) | Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection | |
| FR2892413B1 (fr) | Nouveaux derives d'amino-acides, leur procede de preparation et leur utilisation therapeutique | |
| NO20052264L (no) | Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser | |
| EA201070603A1 (ru) | Лекарственное средство, активное в отношении невропатической боли | |
| WO2008028805A3 (de) | Verwendung einer pharmazeutischen zusammensetzung enthaltend ein anticholinergikum zur abtötung von mikroorganismen und zur behandlung von atemwegsinfektionen | |
| DK1696954T3 (da) | Vaccinesammensætning blandet med en alkylphosphatidylcholin | |
| BR0317263A (pt) | Ligantes alfa2delta para o tratamento de fibromialgia e outras perturbações | |
| BRPI0412826A (pt) | n-[3-(3-substituìdo-pirazolo[1,5-a]pirimidin-7-il)fenil]-s ulfonamidas e compositions e métodos relacionados a ele |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |